IMPEL PHARMACEUTICALS INC (IMPL) [Rocket]

In millions, except per share items	Dec-31-22	Dec-05-22	Dec-31-21	Dec-05-21	Dec-31-20	Dec-05-20	Dec-31-19
	10-K	8-K	10-K	8-K	10-K	8-K	S-1
Revenues [+]	12.7	12.7	0.7	0.7	0.0	0.0	0.0
Products		12.7		0.7
Revenue growth	1794.0%	1794.0%
Cost of goods sold	6.5	6.5	0.7	0.7	0.0	0.0	0.0
Gross profit	6.2	6.2	0.0	0.0	0.0	0.0	0.0
Gross margin	48.7%	48.7%	-3.4%	-3.4%
Selling, general and administrative [+]	77.9	77.9	50.9	50.9	17.0	17.0	12.8
General and administrative	77.9		50.9		17.0		12.8
Research and development	11.5	11.5	20.6	20.6	28.3	28.3	28.8
Other operating expenses	-1.8		-1.7
EBITDA [+]	-80.2		-68.7		-44.3		-40.8
EBITDA growth	16.7%	16.4%	55.2%	57.7%	8.4%
EBITDA margin	-633.8%	-657.5%	-10284.1%	-10701.5%
Depreciation and amortization	1.2		1.1		1.1		0.7
EBIT [+]	-81.4	-83.2	-69.8	-71.5	-45.3	-45.3	-41.6
EBIT growth	16.6%	16.4%	53.9%	57.7%	9.1%
EBIT margin	-643.3%	-657.5%	-10447.0%	-10701.5%
Non-recurring items	1.8		1.7
Interest expense, net [+]	13.8	13.8	4.2	4.2			-0.4
Interest expense	13.8	13.8	4.2	4.2
Interest income							0.4
Other income (expense), net	-9.3	-9.3	-0.8	-0.8	-0.5	-0.5	-0.7
Pre-tax income	-106.3	-106.3	-76.5	-76.5	-45.8	-45.8	-41.8
Income taxes	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%
Net income	-106.3	-106.3	-76.7	-76.7	-46.3	-46.3	-42.4
Net margin	-840.3%	-840.3%	-11476.8%	-11476.8%

Basic EPS [+]	($4.53)	($4.53)	($5.25)	($5.25)	($91.05)	($91.05)	($122.07)
Growth	-13.6%	-13.6%	-94.2%	-94.2%	-25.4%
Diluted EPS [+]	($4.53)	($4.53)	($5.25)	($5.25)	($91.05)	($91.05)	($122.07)
Growth	-13.6%	-13.6%	-94.2%	-94.2%	-25.4%

Shares outstanding (basic) [+]	23.4	23.4	14.6	14.6	0.5	0.5	0.3
Growth	60.6%	60.6%	2770.3%	2770.3%	46.6%
Shares outstanding (diluted) [+]	23.4	23.4	14.6	14.6	0.5	0.5	0.3
Growth	60.6%	60.6%	2770.3%	2770.3%	46.6%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.